Actively Recruiting
Prostate SABR With Intra-Prostatic SABR Boost
Led by King Saud University · Updated on 2020-01-02
30
Participants Needed
1
Research Sites
361 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Stereotactic Ablative Radiation (SABR/SBRT) will be prescribed to a dose of 35 Gy in 5 fractions, once weekly to prostate with a simultaneous intra-prostatic boost to the MR detected nodule up to 50Gy. The pelvic lymph nodes and seminal vesicles will also receive 25 Gy in 5 weekly fractions.
CONDITIONS
Official Title
Prostate SABR With Intra-Prostatic SABR Boost
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed prostate adenocarcinoma
- High-risk prostate cancer defined by at least one of the following: T3 stage, Gleason score 8-10, or PSA greater than 20 ng/mL
- Willingness to provide informed consent to participate in the clinical trial
You will not qualify if you...
- Prior pelvic radiotherapy
- Contraindications to radical prostate radiotherapy such as connective tissue disease or inflammatory bowel disease
- Contraindication to prostate MRI
- No evidence of castrate resistance, defined as PSA less than 3 ng/mL while testosterone is less than 0.7 nmol/L; patients on combined androgen blockade started due to PSA progression are excluded
- Presence of definitive extrapelvic nodal or distant metastatic disease on staging investigations
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
King Saud University Medical City
Riyadh, Saudi Arabia
Actively Recruiting
Research Team
Y
Yasir Alayed, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here